173 results on '"Peulen, Heike"'
Search Results
2. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results
3. Dutch national guidelines for locally recurrent rectal cancer
4. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study
5. Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort
6. Intraoperative Electron Beam Radiation Therapy (IOERT) Versus High-Dose-Rate Intraoperative Brachytherapy (HDR-IORT) in Patients With an R1 Resection for Locally Advanced or Locally Recurrent Rectal Cancer
7. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
8. SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial
9. Post-operative complications following dose adaptation of intra-operative electron beam radiation therapy in locally advanced or recurrent rectal cancer
10. Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC LungTech trial
11. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: The impact of a local dose–effect relationship for lung perfusion loss
12. 1935: Early Quality-of-Life after metastases-directed SBRT– results of the ESTRO & EORTC OligoCare cohort
13. 414: Multidisciplinary approach to target volume delineation in recurrent rectal cancer: a pilot study
14. Quality assurance of four-dimensional computed tomography in a multicentre trial of stereotactic body radiotherapy of centrally located lung tumours
15. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
16. Impact of Quality Assurance of chemoradiotherapy in patients undergoing curative treatment for Locally Recurrent Rectal Cancer
17. Safety of dose adaptation and escalation of Intraoperative Electron Beam Radiation Therapy (IOERT) for locally advanced or recurrent rectal cancer.
18. Locally recurrent rectal cancer: oncological outcomes of neoadjuvant chemoradiotherapy with or without induction chemotherapy
19. Locally recurrent rectal cancer: Oncological outcomes for patients with a pathological complete response after neoadjuvant therapy
20. Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer
21. Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients
22. Dose–effect analysis of radiation induced rib fractures after thoracic SBRT
23. Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group
24. Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer
25. Supplementary File 6: Pulmonary Function Tests and Pulmonary Adverse Events by Treatment Arm. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
26. Supplementary File 2: Treatment details. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
27. Supplementary File 5: Esophageal Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
28. Supplementary File 3: Dose Limiting Toxicity. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
29. Supplementary File 1: Supplementary Methods. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
30. Supplementary File 4: Adverse Events. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
31. Supplementary File 8: Olaparib Pharmacokinetics. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
32. Supplementary File 7: Loco-regional control and survival. from Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
33. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
34. Evaluation of oncologic outcomes of initial locally recurrent rectal cancer versus re-recurrence rectal cancer
35. Multidisciplinary, consensus-based target volume definition in locally recurrent rectal cancer
36. Locally recurrent rectal cancer: Oncological outcomes for patients with a pathological complete response after neoadjuvant therapy
37. Locally recurrent rectal cancer: oncological outcomes of neoadjuvant chemoradiotherapy with or without induction chemotherapy
38. Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
39. Intrafraction Motion in Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer: Intensity Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy
40. Validation of automatic segmentation of ribs for NTCP modeling
41. Development of a consensus-based delineation guideline for locally recurrent rectal cancer
42. Mid-ventilation based PTV margins in Stereotactic Body Radiotherapy (SBRT): A clinical evaluation
43. Development of a consensus-based delineation guideline for locally recurrent rectal cancer
44. Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer
45. Forward Intensity-Modulated Radiotherapy Planning in Breast Cancer to Improve Dose Homogeneity: Feasibility of Class Solutions
46. Intraoperative Electron Beam Radiation Therapy (IOERT) Versus High-Dose-Rate Intraoperative Brachytherapy (HDR-IORT) in Patients With an R1 Resection for Locally Advanced or Locally Recurrent Rectal Cancer
47. Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
48. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
49. Radiotherapy Augments Pembrolizumab Responses and Outcomes in Metastatic Non-Small Cell Lung Cancer: Pooled Analysis of Two Randomized Trials
50. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.